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Abstract  
Renal-related disease is the most common cause of tuberous sclerosis complex (TSC)–related death in 
adults, and renal angiomyolipomas can lead to complications that include chronic kidney disease (CKD) 
and hemorrhage. International TSC guidelines recommend mammalian target of rapamycin (mTOR) 
inhibitors as first-line therapy for management of asymptomatic, growing angiomyolipomas >3 cm in 
diameter. This review discusses data regarding patient outcomes that were used to develop current 
guidelines for embolization of renal angiomyolipomas and presents recent data on 2 available mTOR 
inhibitors—sirolimus and everolimus—in the treatment of angiomyolipoma. TSC-associated renal 
angiomyolipomas can recur after embolization. Both sirolimus and everolimus have shown effectiveness 
in reduction of angiomyolipoma volume, with an acceptable safety profile that includes preservation of 
renal function with long-term therapy. The authors propose a hypothesis for mTORC1 haploinsufficiency 
as an additional mechanism for CKD and propose that preventive therapy with mTOR inhibitors might 
have a role in reducing the number of angiomyolipoma-related deaths. Because mTOR inhibitors target 
the underlying pathophysiology of TSC, patients might benefit from treatment of multiple 
manifestations with 1 systemic therapy. Based on recent evidence, new guidelines should be considered 
which support earlier initiation of mTOR inhibitor therapy for the management of renal 
angiomyolipomas to prevent future serious complications, rather than try to rescue them after the 
complications have occurred.  
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Overview of Renal Disease in Tuberous Sclerosis Complex 
Guidelines relevant for TSC-related angiomyolipoma, including updated diagnostic criteria and 
surveillance and management recommendations, were developed from the second International TSC 
Consensus Conference in Washington, DC [1,2], in which 79 experts from 14 countries participated. 
Table 1 summarizes the surveillance and management recommendations relevant to the kidney. The 
nephrology subcommittee recommended the use of mammalian target of rapamycin (mTOR) inhibitors 
for first-line therapy for management of asymptomatic, growing angiomyolipomas >3 cm in diameter 
[1,2]. These guidelines were based on a search of PubMed and Scopus databases performed on March 
12, 2012, for the consensus guidelines [2] and of the OVID database from 2000 to 2014. This review is 
based on those and subsequent relevant published papers. 
The renal presentation of tuberous sclerosis complex (TSC) most often encompasses renal cysts, 
angiomyolipoma, impaired kidney function and, more rarely, renal cell carcinoma (RCC) [3,4]. Cysts 
occur in approximately 30-45% of patients with TSC and may be associated with kidney failure and 
hypertension [4]. The TSC2 and PKD1 contiguous gene deletion syndrome affects approximately 1 in 20 
patients with TSC. People with this syndrome have deletions involving both the TSC2 and the PKD1 
genes [5]; in these patients, cystic disease is severe and commonly associated with early renal failure. 
Angiomyolipomas are benign tumors composed of blood vessels, smooth muscle cells, and adipose 
tissue [1]. They are rarely reported extra-renally but occur in the kidneys in up to 80% of patients with 
TSC and contribute to renal disease as the most common cause of TSC-related death (Kingswood JC et 
al. The natural history of renal angiomyolipomata in tuberous sclerosis complex. Presented at the 49th 
ERA-EDTA Congress; 24–27 May 2012; Paris, France; unpublished data) [5]. A strong association 
between age, angiomyolipoma size, and chronic kidney disease (CKD) has been reported; patients with 
higher CKD stage tend to be older and have more advanced angiomyolipoma [6]. CKD may develop as a 
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result of loss of renal parenchyma because of growth of angiomyolipoma or cysts, or as a complication 
from surgery or embolization [3,6]. Fat-poor angiomyolipomas (i.e. the epithelioid variant) are 
commonly observed in patients with TSC, whereas, in the general population, they account for <0.1% of 
angiomyolipomas [1,4]. RCCs (occurring in 2–3% of patients with TSC) [4] may be confused diagnostically 
with fat-poor angiomyolipomas [7,8]. Contrast enhanced magnetic resonance imaging (MRI) or 
computed tomography (CT) may help in making this differentiation but it remains challenging even in 
high volume centers. Biopsy might nevertheless be needed. A slower growth rate has been postulated 
as another way to distinguish fat-poor angiomyolipoma from RCC [8].  
 
A retrospective analysis assessed the risk of long-term renal outcomes, including CKD, by evaluating 
records from patients diagnosed with TSC who were included in the UK Clinical Practice Research 
Datalink (CPRD) linked to the Hospital Episode Statistics database (Kingswood JC et al. Real-world 
assessment of renal involvement in tuberous sclerosis complex (TSC) patients in the United Kingdom 
(UK); Presented at the European Association of Urology; 11–15 April 2014; Stockholm, Sweden; 
unpublished data). [9] Overall, 105 of 341 total TSC patients (31%) had renal involvement (defined as 
presence of renal cysts, polycystic kidney disease, CKD, kidney stones, or kidney neoplasms such as 
angiomyolipomas). Among adult patients, 38% (91 of 237 patients) had recognized renal involvement or 
renal-related comorbidity (CKD, 35%; single cyst, 16%; hematuria, 21%; anemia, 21%). The prevalence of 
CKD (stage 3−5) in the TSC population up to age 64 years was greater in every age group compared with 
the UK general population. The crude prevalence estimates showed that TSC patients developed stage 
3+ CKD 30 years earlier than the general UK population, and rates of stage 3+ CKD were more than 5 
times higher than in the general UK population (relative risk = 5.4, 95% CI: 3.7−8.0; p < 0.001) 
(Kingswood JC et al. Real-world assessment of renal involvement in tuberous sclerosis complex (TSC) 
  
6 
 
patients in the United Kingdom (UK); Presented at the European Association of Urology; 11–15 April 
2014; Stockholm, Sweden; unpublished data) [9]. 
 
Patients with TSC-associated angiomyolipoma have an increased risk for hemorrhage, with risk factors 
considered to be angiomyolipoma size (>3 cm or >4 cm), aneurysm size >0.5 cm, and serial growth [3] 
(Kingswood JC et al. The natural history of renal angiomyolipomata in tuberous sclerosis complex. 
Presented at the 49th ERA-EDTA Congress; 24–27 May 2012; Paris, France; unpublished data)[1,5]. 
Although small angiomyolipomas are usually asymptomatic, angiomyolipomas шϰ cm become 
symptomatic in 68–80% of patients, with 50–60% presenting as hemorrhage [9].  
 
Renal complications associated with TSC were also assessed in retrospective analyses of natural history 
data collected from 2 large databases (reported by Kingswood JC et al. The natural history of renal 
angiomyolipomata in tuberous sclerosis complex. Presented at the 49th ERA-EDTA Congress; 24–27 May 
2012; Paris, France; unpublished data) [5]. The first analysis evaluated retrospective data collected by 
questionnaires from 296 patients with TSC in the UK Renal Registry. Twenty-seven of 52 patients (52%) 
with serial measurements of angiomyolipoma lesions captured over 5 years showed growth. Serial 
growth was found to be a risk factor for bleeding (21% of patients with growing angiomyolipomas 
experienced renal bleeding, compared with only 4% of patients with stable angiomyolipomas; X2 = 7.42; 
p < 0.01). The second analysis evaluated data from 278 patients with TSC who were followed up at the 
St. George’s Hospital Clinic (London, UK), of whom 130 had renal angiomyolipoma. Data were analyzed 
from 53 adults with TSC and renal angiomyolipoma for whom serial imaging data were available. Sixty-
seven percent of the angiomyolipomas exhibited serial growth in these adults, with a mean rate of 
growth of 5.5 mm/year. The growth rate of the angiomyolipomas was not correlated with size of lesion 
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or age of patient, although growth rate tended to be greater in younger patients (Kingswood JC et al. 
The natural history of renal angiomyolipomata in tuberous sclerosis complex. Presented at the 49th 
ERA-EDTA Congress; 24–27 May 2012; Paris, France; unpublished data) [5]. 
 
Outcome of Intervention 
Based on a search of PubMed and Scopus databases performed on March 12, 2012, for the consensus 
guidelines [11] and of the OVID database from 2000 to 201From our review4, we identified 16 case 
series that reported embolization of renal angiomyolipoma with sufficient data to characterize patient 
details and outcomes (supplemental table 1). Thereby, we found that after embolization, approximately 
25% of TSC-associated renal angiomyolipoma recur.  
 
The incidence of CKD was assessed in a retrospective chart review of a TSC cohort treated in a single 
center in the Netherlands [10]. The mean duration of follow-up was 15.8 years, and the median age at 
the end of follow-up was 40 years. Of 351 patients with TSC, 244 (69.5%) had confirmed renal 
angiomyolipoma. Patients were assigned a renal angiomyolipoma stage (from none detected to 6) based 
on the number of angiomyolipomas in both kidneys, size of angiomyolipoma, and kidney anatomy (Table 
2). Fifty-nine percent of patients (144 of 244) with a confirmed renal angiomyolipoma reached a highest 
angiomyolipoma stage ≥3, which indicated that the patient was at a high risk for hemorrhage and was a 
candidate for elective embolization. Hypertension, anemia, impaired kidney function, and need for 
blood transfusions increased with angiomyolipoma stage. Patients in higher stages were more likely to 
require more embolization. Yearly embolization rates ranged from 0.08 to 0.14 depending on 
angiomyolipoma stage, suggesting that patients with large, growing asymptomatic angiomyolipomas will 
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require an embolization every 7–11 years. Additionally, impaired kidney function was more common in 
patients who had undergone embolization (29%) than in those who had not (10%) [10].  
 
Effectiveness/Risk of mTOR Inhibitors  
mTOR inhibitors represent the first systemic approach to treating the underlying pathophysiology of TSC 
disease by blocking the activation of mTOR complex 1 and downstream signaling (fig. 1) [4][2]. Two oral 
mTOR inhibitors—sirolimus and everolimus—have been evaluated for management of angiomyolipoma 
(supplemental table 2). Four small, open-label studies showed the effectiveness of sirolimus in 
management of renal angiomyolipoma [11-14].  
 
The data for effects of everolimus on angiomyolipoma are more robust; results from 2 large 
randomized, double-blind, placebo-controlled, phase 3 trials are available [15,16]. In a subgroup analysis 
of patients in the EXIST-1 trial, after a median follow-up duration of 9.7 months, angiomyolipoma 
response rate (an exploratory end point) was 53.3% for everolimus compared with 0% for placebo. 
Angiomyolipoma volume reductions with everolimus were sustained over 48 weeks of treatment 
(fig. 21) [17][19]. In EXIST-2, the primary end point of angiomyolipoma response was achieved in 42% of 
patients (33 of 79) compared with 0% for placebo (0 of 39, p < 0.0001) after a median everolimus 
exposure of 8.7 months, and the median time to reach an angiomyolipoma response was 2.9 months 
[15]. Data from an open-label extension of the EXIST-2 study showed sustained reduction in 
angiomyolipoma volume to at least 192 weeks of treatment (fig. 32), with an angiomyolipoma response 
rate of 56.3% (63 of 112 patients) over a median 39.8 months of everolimus exposure. Among the 63 
patients achieving angiomyolipoma response at any time, only 2 progressions were observed. Long-term 
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data show continued shrinkage of angiomyolipoma with everolimus therapy. Notably, at this cutoff, no 
bleeding was observed with everolimus in a population with high risk for bleeding events before 
initiation of mTOR inhibitor therapy (Bissler JJ et al. Everolimus for renal angiomyolipoma associated 
with tuberous sclerosis complex (TSC) from EXIST-2: continued efficacy and diminishing adverse events 
after ~3.5 years of treatment. Presented at the 30th Annual European Association of Urology Congress; 
20–24 March 2015; Madrid, Spain; unpublished data).[20]. 
 
Safety of mTOR Inhibitors 
Class effects of mTOR inhibitors include stomatitis/mucositis/mouth ulceration (~50%), 
hypercholesterolemia (20–40%), hypertriglyceridemia (12–50%), infections (40–70%, hypophosphatemia 
(11%), amenorrhea (13–38%), hematologic abnormalities (leukopenia, neutropenia, 10–40%), and 
proteinuria (4–30%) [11-16]. The EXIST-2 extension data show a decrease in the number of newly 
emergent adverse effects over time [18][20,21]. In addition, data from the 3.5-year analysis of EXIST-2 
reported that severe renal impairment (glomerular filtration rate [GFR] <30 ml/min/1.73 m2) was 
observed in only 7.1% of patients, all of whom had compromised renal function prior to everolimus 
initiation. Furthermore, overall, GFR remained stable over time; median GFR at baseline was 85 
mL/min/1.73 m2, and median GFR at Week 120 was 84 mL/min/1.73 m2 (Bissler JJ et al. Everolimus for 
renal angiomyolipoma associated with tuberous sclerosis complex (TSC) from EXIST-2: continued 
efficacy and diminishing adverse events after ~3.5 years of treatment. Presented at the 30th Annual 
European Association of Urology Congress; 20–24 March 2015; Madrid, Spain; unpublished data). 
[20][20]. This might suggest preservation of renal function with everolimus treatment in patients who 
did not have pre-existing kidney impairment.  
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Potential Mechanisms for Renal Complications 
CKD may not be entirely attributable to angiomyolipoma hemorrhage and subsequent treatment (i.e. 
surgery/embolization). A mechanism independent of bleeding may occur where large, benign 
angiomyolipomas encroach on normal renal tissue and lead to CKD [4]. We propose 2 additional 
hypotheses for the development of CKD. The first postulates that normal replacement renal tissue 
becomes TSC tissue because of somatic second-hit mutations [19] occurring during rapid cell division 
(when the kidney still has growth and repair potential at age <35−40 years); this wcould cause an 
accelerated loss of normal renal tissue leading to CKD. A second hypothesis is that TSC1 or TSC2 
haploinsufficiency may lead to modest mTORC1 overactivity and, therefore, glomerular hypertrophy and 
hyperfiltration. It has been postulated that mTORC1 overactivity is a mechanism of CKD progression, 
especially in diabetic nephropathy [20] and may be 1 mechanism by which patients with TSC develop 
CKD in middle age. Data show that mTOR is activated in patients with diabetic nephropathy and that 
inhibition of mTOR signaling prevented glomerulosclerosis and ameliorated progression of glomerular 
disease in a mouse model [21]. In addition, either haploinsufficiency or second somatic mutation in the 
tubule cells could predispose to premature apoptosis or maldifferentiation, or might be associated with 
loss of function due to an undiscovered novel mechanism (e.g. microcysticcyctic renal disease) that may 
not be identified by imaging. If this hypothesis is correctTherefore, mTOR inhibition might help 
ameliorate loss of GFR independent of its effect on renal angiomyolipomas.TSC1/2 haploinsufficiency 
also may predispose patients with TSC to renal damage and premature CKD even in those without a 
severe angiomyolipoma burden. However, it has also been postulated that mTOR inhibition may 
potentially worsen progression of CKD [20,21], and additional research in this area is necessary.  
 
Defining aInvestigating a Possible New Treatment Paradigm 
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We propose a clinical trial in whichthat mTOR inhibitors arebe used as preventative therapy, not just as 
therapy. The use of mTOR inhibitors is nephron sparing, compared with embolization or surgery, and 
usually prevents further growth of angiomyolipoma [3]. Patients with TSC have a high a priori risk for 
severe renal disease, with approximately 40% progressing to CKD by age 45–54 years (Kingswood JC et 
al. Real-world assessment of renal involvement in tuberous sclerosis complex (TSC) patients in the 
United Kingdom (UK); Presented at the European Association of Urology; 11–15 April 2014; Stockholm, 
Sweden; unpublished data) [10][9]. Data from EXIST-1 and –EXIST-2 support the success of early 
treatment in preventing progression of renal disease. If haploinsufficiency of TSC1/2 does cause 
hyperfiltration, as proposed herein, then the risks of mTOR inhibitors may be counterbalanced by the 
increased benefit of downregulating mTOR overactivity in affected cells. However, there is no published 
evidence in humans yet to support any benefit beyond controlling angiomyolipomas. Furthermore, the 
current published evidence suggests that angiomyolipomas regrow if mTOR inhibitor therapy is 
discontinued [11,13], so that therapy may need to be lifelong. patients with TSC will be at risk for CKD 
even if they have no overt angiomyolipomas. This concern must be evaluated in trials and additional 
epidemiologic studies. The ongoing Tuberous Sclerosis Registry to Increase Disease Awareness (TOSCA) 
might enable studies to address this issue.  
 
Preliminary evidence has shown that early treatment of renal angiomyolipomas in children prevents 
progression and preserves renal function [17]. To date, follow-up data have shown that risk for serious 
adverse events in this population is low and suggest that growth and physical development in treated 
children are normal, although long term issues such as potential effects on fertility necessitate further 
study [22].  
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Patients with TSC are at lifelong risk for appearance and progression of many of TSC-associated 
complications. With the availability of oral mTOR inhibitors, the underlying pathogenic dysregulation of 
mTORC1 signaling can be controlled, which might allow multiple clinical manifestations to be treated 
with a single targeted therapy. The potential benefits of preventative therapy in reducing 
angiomyolipoma-related morbidities may the number of angiomyolipoma-related deaths may well 
outweigh the risks of long-term therapy. Furthermore, because other complications of TSC also respond 
to mTOR inhibitor therapy, including subependymal giant cell astrocytomas (SEGAs) [16], facial 
angiofibromasskin rash [15,16], lymphangioleiomyomatosis (LAM) [23,24], and epilepsy [25], a holistic 
approach to preventive therapy might be appropriate to avoid many serious manifestations of the 
condition. 
 
Conclusions 
Based on recent evidence, the 2012 internationalnew guidelines for the management of 
angiomyolipomas should be updated to include the use considered for earlier initiation of mTOR 
inhibitor therapy as first choice for pre-emptive treatment of growing angiomyolipomas >3 cm in 
diameter. In addition, we propose a new study to determine the efficacy and risks of initiating 
preventative treatment in younger patients with a high angiomyolipoma burden (e.g. >5) before they 
grow larger than 3 cm. to prevent future serious complications. Whether this guidance should be based 
on the diagnosis of TSC (given the high a priori risk) or when renal angiomyolipoma burden first 
becomes more severe (e.g. >5 angiomyolipomas of any size) has yet to be determined. 
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Table 1. Kidney-related surveillance and management recommendations of the International 
Tuberous Sclerosis Complex Consensus Group [2] 
Surveillance of kidneys 
Newly diagnosed or suspected TSC Diagnosed with definite or possible TSC 
 Obtain MRI of the abdomen to 
assess for the presence of 
angiomyolipoma and renal cysts 
 Screen for hypertension by 
obtaining accurate BP 
 Evaluate renal function by 
determining GFR 
 Obtain abdominal MRI of the abdomen to 
assess angiomyolipoma progression and 
renal cystic disease (every 1−3 years for 
life) 
 Assess renal function (GFR and BP) at least 
annually 
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Management recommendations for renal angiomyolipoma 
Clinical presentation Recommendation 
 Angiomyolipoma with acute 
hemorrhage 
 Embolization (followed by corticosteroids 
for 7 days to mitigate post-embolization 
syndrome) [26]. Embolization should be as 
selective as technically feasible to 
preserve renal parenchyma 
 Avoid nephrectomy 
 Asymptomatic, growing 
angiomyolipoma >3 cm in 
diameter 
 First-line: mTOR inhibitor 
 Second-line: selective embolization or 
kidney-sparing resection 
BP = blood pressure; GFR = glomerular filtration rate. 
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Table 2. Renal angiomyolipoma staging criteria proposed in a retrospective study.  
 
aAngiomyolipoma not detectable or lesions < 1 cm unidentifiable as angiomyolipoma. 
Reprinted with permission from Eijkemans et al. [12]. 
  
Stage   Description of kidney 
anatomy Angiomyolipoma number Angiomyolipoma size 
None 
detecteda 
NoŶe ш1 Đŵ iŶ loŶgest 
diameter 
- Normal 
1 чϱ <3.5 cm Normal 
2 ˃5 <3.5 cm Normal 
3 чϱ At least 1 шϯ.ϱ Đŵ Kidney intact 
4 ˃5 1 to 4 ш3.5 cm Kidney intact 
5 ˃5 ϱ or ŵore шϯ.ϱ cm Kidney recognizable 
6 ˃5 At least 1 ш5.0 cm Kidney not recognizable 
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Figure Captions 
Fig. 1. The mTOR pathway.  
Fig. 12. Percentage change from baseline of sum of volumes (cm3) of target angiomyolipoma lesions by 
time window. Percentages were calculated relative to the number of patients evaluated at baseline and 
at the corresponding visit. Reproduced with permission from Kingswood et al. [17]. 
Fig. 23. Long-term efficacy of everolimus from EXIST-2: proportion of patients with ш30% or ш50% 
reduction in angiomyolipoma volume over time (Bissler JJ et al. Everolimus for renal angiomyolipoma 
associated with tuberous sclerosis complex (TSC) from EXIST-2: continued efficacy and diminishing 
adverse events after ~3.5 years of treatment. Presented at the 30th Annual European Association of 
Urology Congress; 20–24 March 2015; Madrid, Spain; unpublished data). 
 
